Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Acne Vulgaris - Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 19 Dec 17

The "Acne Vulgaris - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Acne Vulgaris - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Acne Vulgaris (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acne Vulgaris (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 12, 20, 9, 1, 17, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Acne Vulgaris (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Acne Vulgaris - Overview
  3. Acne Vulgaris - Therapeutics Development
  4. Acne Vulgaris - Therapeutics Assessment
  5. Acne Vulgaris - Companies Involved in Therapeutics Development
  6. Acne Vulgaris - Drug Profiles
  7. Acne Vulgaris - Dormant Projects
  8. Acne Vulgaris - Discontinued Products
  9. Acne Vulgaris - Product Development Milestones
  10. Appendix

  • 3SBio Inc
  • Almirall SA
  • Biomar Microbial Technologies
  • BioPharmX Inc
  • Blueberry Therapeutics Ltd
  • Braintree Laboratories Inc
  • Brickell Biotech Inc
  • Cassiopea SpA
  • Celtaxsys Inc
  • Common Pharma Inc
  • Cutanea Life Sciences Inc
  • Deltanoid Pharmaceuticals Inc
  • Dermira Inc
  • Eligo Bioscience SAS
  • ELORAC Inc
  • Ensol Biosciences Inc
  • Helix BioMedix Inc
  • Hovione FarmaCiencia SA
  • Innovation Pharmaceuticals Inc
  • Lee's Pharmaceutical Holdings Ltd
  • LEO Pharma A/S
  • Melinta Therapeutics Inc
  • Novan Inc
  • Novartis AG
  • Paratek Pharmaceuticals Inc
  • Pfizer Inc
  • Phosphagenics Ltd
  • Realm Therapeutics Plc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Sol-Gel Technologies Ltd
  • Sun Pharmaceutical Industries Ltd
  • Taro Pharmaceutical Industries Ltd
  • Valeant Pharmaceuticals International Inc
  • Vyome Biosciences Pvt Ltd
  • XBiotech Inc

For more information about this report visit

View source version on

Business Wire

Last updated on: 19/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.